<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01155531</url>
  </required_header>
  <id_info>
    <org_study_id>THR-4450-C-401</org_study_id>
    <nct_id>NCT01155531</nct_id>
  </id_info>
  <brief_title>Safety &amp; Tolerability of a Combination of Antidepressant and Peptic Ulcer Drug in Overweight Healthy Subjects</brief_title>
  <official_title>A Phase I, Single Center, Open Label, Intra Subject, Dose Escalation Study to Evaluate Safety and Tolerability of Sertraline Plus Telenzepine in Overweight Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theracos</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theracos</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of this study is that up to 150 mg of sertraline and up to 3 mg of telenzepine
      will be safe, tolerable, and have the effect of suppressing appetite, when taken in
      combination daily by mouth by healthy, overweight, adult men and women.

      In this study, up to 12 people will be assigned to one of 4 groups: A, B, C, and D, and will
      receive 0, 50, 100, or 150 mg of sertraline per day. People in Groups B, C, or D will receive
      an initial dose of 50 mg sertraline. People in Groups C and D will receive an additional 50
      mg of sertraline per week.

      Up to 10 people from each group who were able to tolerate their sertraline dose for at least
      5 days will begin taking 50 mg of sertraline plus doses of telenzepine that will increase
      from 1 mg to 2 mg to 3 mg over a 7-day period (they will receive each combination). On the
      day before they begin taking this combination of drugs, their appetite will be evaluated (on
      a visual scale of 0 to 100) before and after 3 meals.

      The appetites of each person, assessed by the visual scale, will be evaluated on the last day
      of the period (Day 7) before and after 3 meals of each combination treatment, while they are
      staying in the research unit. The amount of food they eat will be determined.

      Based on safety and tolerability assessments of individuals, and of the previous groups who
      received lower doses of the combination of drug, a decision will be made whether to further
      increase the dose of these drugs.

      Since the appetites of each person will be evaluated on the last day of the period (Day 7)
      before and after 3 meals of each combination treatment, people in this study will stay in the
      research unit for approximately 2Â½ days, starting on Day 6 of their previous treatment, so
      appetite evaluations can be made on Day 7 after a fixed meal in the evening of Day 6. These
      people will continue the stay in the research unit when they begin each telenzepine dose
      increase, so a 24 hour safety observation may be made immediately after the increase.

      After the final doses of telenzepine have been received, people in Groups C and D will
      continue to receive sertraline 50 mg per day for an additional 7 days or until the study
      physician decides when sertraline should be discontinued. People will return to the study
      unit for final visit, 2 weeks after they have received their last sertraline dose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the VAS Score From Baseline.</measure>
    <time_frame>The baseline was defined on day 7 of sertraline treatment with no telenzepine before and meal. Appetite VAS was measured 30 min before and 1hour after to meal</time_frame>
    <description>The baseline VAS self-assessment was completed for each subject on day 7 of each dose combination. Appetite VAS was completed in the subject's room approximately 30 min before and 1 h after each meal serving. Appetite was not assessed prior to snacks. VAS assessment was based on response to the question: &quot;How hungry are you now?&quot; The anchor points of the 100mm scale were &quot;I am not hungry at all&quot; and &quot;Never more hungry&quot; corresponding to 0 mm and 100 mm respectively. The subjects' VAS scores were measured by the clinic staff and entered into the CRF. The description listed below (VAS after meal minus and VAS before meal) refers only to the mean VAS score of each group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in the Meal Calories Consumed</measure>
    <time_frame>The baseline was defined as on day 7 of sertraline treatment with no telenzepine. Food consumption was measured as calories consumed for breakfast, lunch, and dinner for all treatment groups on day 7 of each dose combination.</time_frame>
    <description>The changes in the meal calories consumed was measured upon telenzepine treatment at the dose of 1 mg, 2 mg and 3 mg (i.e. end of every 7 days). The baseline was defined as on day 7 of sertraline treatment with no telenzepine for the specified meal. Food consumption was measured as calories consumed for breakfast, lunch, and dinner for all treatment groups on day 7 of each dose combination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of Sertraline and Telenzepine Combination</measure>
    <time_frame>7 days</time_frame>
    <description>safety of the drug combination was measured in terms of number of adverse events during the study period.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Telenzepine - Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group A: No Sertraline; 0, 1, 2, 3 mg/day Telenzepine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sertraline plus Telenzepine - Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sertraline 50 mg/day; 0, 1, 2, 3 mg/day Telenzepine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sertraline plus Telenzepine - Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sertraline 50, 100 mg/day; 0, 1, 2, 3 mg/day Telenzepine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sertraline plus Telenzepine - Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sertraline 50, 100, 150 mg/day; 0, 1, 2, 3 mg/day Telenzepine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline plus Telenzepine</intervention_name>
    <description>oral sertraline tablets at 0, 50, 100, or 150/day plus oral telenzepine capsules at 0, 1, 2, or 3 mg/day for 7 days in each combination</description>
    <arm_group_label>Telenzepine - Group A</arm_group_label>
    <arm_group_label>Sertraline plus Telenzepine - Group B</arm_group_label>
    <arm_group_label>Sertraline plus Telenzepine - Group C</arm_group_label>
    <arm_group_label>Sertraline plus Telenzepine - Group D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In good health based on medical history, physical examination, ECG, routine laboratory
             tests, and BMI &gt;/= 30 kg/m2 and &lt;/=30 40 kg/m^2.

          -  Males and females agree to use described birth control methods.

          -  Non-smoker.

          -  Willing and able to be confined to the clinical research facility.

          -  Willing and able to comply with the protocol and able to communicate with
             investigators.

          -  Able to comprehend and willing to provide written informed consent.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, neurologic, or allergic disease
             (including drug allergies; patients with untreated, asymptomatic, seasonal allergies
             may be enrolled), surgical conditions, cancer or any other condition that might in the
             opinion of the investigator impair the ability of the subject to complete the study or
             significantly interfere with the absorption, distribution, metabolism, or excretion of
             the study drugs.

          -  Evidence or history of clinically significant psychiatric disease including major
             depression, mania, or hypomania, and history of suicide attempts or suicidal ideation.
             Subjects with a Beck Depression Inventory-II (BDI-II) score &gt;13 at screening are
             excluded.

          -  Clinically relevant abnormal findings at the screening examination (including
             laboratory tests and ECG).

          -  Screening ECG which demonstrates at least one of the following: heart rate &gt; 100 bpm,
             QRS &gt; 120 msec, QTc &gt; 450 msec, PR &gt; 220 msec or any rhythm other than sinus rhythm,
             sinus bradycardia, or sinus arrhythmia.

          -  Change in weight &gt; 5 kilograms within 3 months of screening.

          -  History of alcohol consumption exceeding 14 drinks/week (1 drink equaling 5 ounces of
             wine, 12 ounces of beer, or 1.5 ounces of hard liquor) within the 6 months before
             study entry.

          -  Sitting systolic blood pressure â¤90 millimeters of mercury (mmHg) or â¥140 mmHg,
             diastolic blood pressure &lt;/= 50 mmHg or &gt;/= 90 mmHg and judged to be clinically
             significant by the investigator.

          -  Positive result on drug screen, hepatitis B surface antigen (HBsAg), hepatitis C
             (HCV), or human immunodeficiency (HIV) tests.

          -  Use of prescription or non-prescription drugs, vitamins, or dietary supplements within
             14 days prior to the first dose of study medication. Subjects on oral contraceptives
             and subjects who have used acetaminophen at doses of &lt; 2 grams/day are eligible for
             study entry. Any exception to this must be felt not to impact the integrity of the
             data and must be jointly agreed upon by the investigator and medical monitor.

          -  Treatment with any investigational drug, use of any known CYP450 enzyme-
             inducing/inhibiting agents (e.g., barbiturates, phenothiazines, cimetidine, St. John's
             Wort) or herbal supplements within 30 days prior to the first dose of study
             medication.

          -  Treatment with any psychotropic medication within 90 days of screening.

          -  History of drug abuse or dependence within 180 days of screening.

          -  Febrile illness within 5 days prior to the first dose of study medication.

          -  Inadequate venous access.

          -  Known allergy to sertraline or telenzepine.

          -  History of an active eating disorder such as anorexia nervosa, bulimia or binge eating
             disorder.

          -  Elevated ALT (&gt; 2X ULN) or total bilirubin (&gt; 1.6 mg/dL)

          -  Have diabetes mellitus (fasting plasma glucose &gt; 126 mg/dL)

          -  Have been on weight loss medications in the past 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jolene Berg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cetero Research, San Antonio</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2010</study_first_submitted>
  <study_first_submitted_qc>June 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2010</study_first_posted>
  <results_first_submitted>August 2, 2011</results_first_submitted>
  <results_first_submitted_qc>December 5, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 9, 2013</results_first_posted>
  <last_update_submitted>March 4, 2015</last_update_submitted>
  <last_update_submitted_qc>March 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Overweight</keyword>
  <keyword>Sertraline</keyword>
  <keyword>Telenzepine</keyword>
  <keyword>Decrease appetite</keyword>
  <keyword>Reduce appetite</keyword>
  <keyword>Lose weight</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sertraline</mesh_term>
    <mesh_term>Pirenzepine</mesh_term>
    <mesh_term>Telenzepine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Telenzepine - Group A</title>
          <description>received Sertraline 0 mg/day for 7 days.After 7 days, received telenzepine for 21 days total at 1, 2, and 3 mg/day for 7 days each.</description>
        </group>
        <group group_id="P2">
          <title>Telenzepine Plus Sertraline - Group B</title>
          <description>received Sertraline 50 mg/day for 7 days. After 7 days, received telenzepine for 21 days total at 1, 2, and 3 mg/day for 7 days each.</description>
        </group>
        <group group_id="P3">
          <title>Telenzepine Plus Sertraline - Group C</title>
          <description>received Sertraline 100 mg/day for 7 days. After 7 days, received telenzepine for 21 days total at 1, 2, and 3 mg/day for 7 days each.</description>
        </group>
        <group group_id="P4">
          <title>Telenzepine Plus Sertraline - Group D</title>
          <description>received Sertraline 150 mg/day for 7 days. After 7 days, received telenzepine for 21 days total at 1, 2, and 3 mg/day for 7 days each.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Telenzepine - Group A</title>
          <description>received Sertraline 0 mg/day for 7 days.After 7 days, received telenzepine for 21 days total at 1, 2, and 3 mg/day for 7 days each.</description>
        </group>
        <group group_id="B2">
          <title>Telenzepine Plus Sertraline - Group B</title>
          <description>received Sertraline 50 mg/day for 7 days. After 7 days, received telenzepine for 21 days total at 1, 2, and 3 mg/day for 7 days each.</description>
        </group>
        <group group_id="B3">
          <title>Telenzepine Plus Sertraline - Group C</title>
          <description>received Sertraline 100 mg/day for 7 days. After 7 days, received telenzepine for 21 days total at 1, 2, and 3 mg/day for 7 days each.</description>
        </group>
        <group group_id="B4">
          <title>Telenzepine Plus Sertraline - Group D</title>
          <description>received Sertraline 150 mg/day for 7 days. After 7 days, received telenzepine for 21 days total at 1, 2, and 3 mg/day for 7 days each.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.7" lower_limit="22" upper_limit="42"/>
                    <measurement group_id="B2" value="35.2" lower_limit="21" upper_limit="45"/>
                    <measurement group_id="B3" value="33.5" lower_limit="22" upper_limit="44"/>
                    <measurement group_id="B4" value="34.3" lower_limit="22" upper_limit="45"/>
                    <measurement group_id="B5" value="33.4" lower_limit="21" upper_limit="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in the VAS Score From Baseline.</title>
        <description>The baseline VAS self-assessment was completed for each subject on day 7 of each dose combination. Appetite VAS was completed in the subjectâs room approximately 30 min before and 1 h after each meal serving. Appetite was not assessed prior to snacks. VAS assessment was based on response to the question: âHow hungry are you now?â The anchor points of the 100mm scale were âI am not hungry at allâ and âNever more hungryâ corresponding to 0 mm and 100 mm respectively. The subjectsâ VAS scores were measured by the clinic staff and entered into the CRF. The description listed below (VAS after meal minus and VAS before meal) refers only to the mean VAS score of each group.</description>
        <time_frame>The baseline was defined on day 7 of sertraline treatment with no telenzepine before and meal. Appetite VAS was measured 30 min before and 1hour after to meal</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Telenzepine - Group A</title>
            <description>received Sertraline 0 mg/day for 7 days.After 7 days, received telenzepine for 21 days total at 1, 2, and 3 mg/day for 7 days each.</description>
          </group>
          <group group_id="O2">
            <title>Telenzepine Plus Sertraline - Group B</title>
            <description>received Sertraline 50 mg/day for 7 days.After 7 days, received telenzepine for 21 days total at 1, 2, and 3 mg/day for 7 days each.</description>
          </group>
          <group group_id="O3">
            <title>Sertraline Plus Telenzepine - Group C</title>
            <description>received Sertraline 100 mg/day for 7 days.After 7 days, received telenzepine for 21 days total at 1, 2, and 3 mg/day for 7 days each.</description>
          </group>
          <group group_id="O4">
            <title>Sertraline Plus Telenzepine - Group D</title>
            <description>received Sertraline 150 mg/day for 7 days.After 7 days, received telenzepine for 21 days total at 1, 2, and 3 mg/day for 7 days each.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the VAS Score From Baseline.</title>
          <description>The baseline VAS self-assessment was completed for each subject on day 7 of each dose combination. Appetite VAS was completed in the subjectâs room approximately 30 min before and 1 h after each meal serving. Appetite was not assessed prior to snacks. VAS assessment was based on response to the question: âHow hungry are you now?â The anchor points of the 100mm scale were âI am not hungry at allâ and âNever more hungryâ corresponding to 0 mm and 100 mm respectively. The subjectsâ VAS scores were measured by the clinic staff and entered into the CRF. The description listed below (VAS after meal minus and VAS before meal) refers only to the mean VAS score of each group.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 mg of Telenzepine (30 min before breakfast)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.90" spread="28.77"/>
                    <measurement group_id="O2" value="2.70" spread="33.05"/>
                    <measurement group_id="O3" value="-10.8" spread="25.72"/>
                    <measurement group_id="O4" value="6.70" spread="22.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 mg of Telenzepine (30 min before breakfast)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.50" spread="34.58"/>
                    <measurement group_id="O2" value="-4.40" spread="24.80"/>
                    <measurement group_id="O3" value="18.50" spread="29.38"/>
                    <measurement group_id="O4" value="-4.5" spread="32.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 mg of Telenzepine (30 min before breakfast)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.22" spread="34.66"/>
                    <measurement group_id="O2" value="-7.60" spread="25.16"/>
                    <measurement group_id="O3" value="14.33" spread="31.86"/>
                    <measurement group_id="O4" value="-4.60" spread="30.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 mg of Telenzepine (1 hour after breakfast)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.50" spread="16.64"/>
                    <measurement group_id="O2" value="-2.40" spread="4.84"/>
                    <measurement group_id="O3" value="-9.60" spread="40.56"/>
                    <measurement group_id="O4" value="1.20" spread="16.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 mg of Telenzepine (1 hour after breakfast)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.30" spread="8.18"/>
                    <measurement group_id="O2" value="-5.20" spread="8.35"/>
                    <measurement group_id="O3" value="0.1" spread="20.90"/>
                    <measurement group_id="O4" value="6.70" spread="23.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 mg of Telenzepine (1 hour after breakfast)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.11" spread="13.01"/>
                    <measurement group_id="O2" value="-7.60" spread="8.90"/>
                    <measurement group_id="O3" value="-2.89" spread="31.85"/>
                    <measurement group_id="O4" value="3.50" spread="23.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 mg of Telenzepine (30 min before lunch)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" spread="18.76"/>
                    <measurement group_id="O2" value="-14.50" spread="17.97"/>
                    <measurement group_id="O3" value="-2.10" spread="26.21"/>
                    <measurement group_id="O4" value="4.60" spread="31.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 mg of Telenzepine (30 min before lunch)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.60" spread="23.32"/>
                    <measurement group_id="O2" value="-16.30" spread="18.85"/>
                    <measurement group_id="O3" value="9.60" spread="24.47"/>
                    <measurement group_id="O4" value="2.40" spread="27.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 mg of Telenzepine (30 min before lunch)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.78" spread="25.37"/>
                    <measurement group_id="O2" value="-23.40" spread="25.91"/>
                    <measurement group_id="O3" value="0.44" spread="21.90"/>
                    <measurement group_id="O4" value="-2.70" spread="19.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 mg of Telenzepine (1 hour after lunch)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2" spread="15.22"/>
                    <measurement group_id="O2" value="-3.90" spread="15"/>
                    <measurement group_id="O3" value="4.60" spread="17.16"/>
                    <measurement group_id="O4" value="11" spread="23.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 mg of Telenzepine (1 hour after lunch)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="12.34"/>
                    <measurement group_id="O2" value="-6.10" spread="9.21"/>
                    <measurement group_id="O3" value="5.70" spread="7.90"/>
                    <measurement group_id="O4" value="2" spread="6.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 mg of Telenzepine (1 hour after lunch)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.44" spread="8.95"/>
                    <measurement group_id="O2" value="-4.60" spread="8.91"/>
                    <measurement group_id="O3" value="12.11" spread="27.78"/>
                    <measurement group_id="O4" value="5.60" spread="22.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 mg of Telenzepine (30 min before supper)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.10" spread="30.35"/>
                    <measurement group_id="O2" value="-1.20" spread="21.87"/>
                    <measurement group_id="O3" value="9.90" spread="26.41"/>
                    <measurement group_id="O4" value="12.50" spread="17.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 mg of Telenzepine (30 min before supper)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.10" spread="19.55"/>
                    <measurement group_id="O2" value="-10.60" spread="17.05"/>
                    <measurement group_id="O3" value="4.50" spread="26.73"/>
                    <measurement group_id="O4" value="12.60" spread="21.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 mg of Telenzepine (30 min before supper)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.67" spread="37.51"/>
                    <measurement group_id="O2" value="-17" spread="23.05"/>
                    <measurement group_id="O3" value="-13.33" spread="30.64"/>
                    <measurement group_id="O4" value="-1" spread="12.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 mg of Telenzepine (1 hour after supper)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.70" spread="7.57"/>
                    <measurement group_id="O2" value="-3.10" spread="16.39"/>
                    <measurement group_id="O3" value="-17" spread="8.38"/>
                    <measurement group_id="O4" value="13.70" spread="19.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 mg of Telenzepine (1 hour after supper)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" spread="7.78"/>
                    <measurement group_id="O2" value="-3.30" spread="15.58"/>
                    <measurement group_id="O3" value="-7" spread="17.33"/>
                    <measurement group_id="O4" value="-3.30" spread="26.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 mg of Telenzepine (1 hour after supper)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.78" spread="3.93"/>
                    <measurement group_id="O2" value="-4.30" spread="14.44"/>
                    <measurement group_id="O3" value="-6.33" spread="16.65"/>
                    <measurement group_id="O4" value="-8.10" spread="26.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Changes in the Meal Calories Consumed</title>
        <description>The changes in the meal calories consumed was measured upon telenzepine treatment at the dose of 1 mg, 2 mg and 3 mg (i.e. end of every 7 days). The baseline was defined as on day 7 of sertraline treatment with no telenzepine for the specified meal. Food consumption was measured as calories consumed for breakfast, lunch, and dinner for all treatment groups on day 7 of each dose combination.</description>
        <time_frame>The baseline was defined as on day 7 of sertraline treatment with no telenzepine. Food consumption was measured as calories consumed for breakfast, lunch, and dinner for all treatment groups on day 7 of each dose combination.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Telenzepine - Group A</title>
            <description>received Sertraline 0 mg/day for 7 days.After 7 days, received telenzepine for 21 days total at 1, 2, and 3 mg/day for 7 days each.</description>
          </group>
          <group group_id="O2">
            <title>Telenzepine Plus Sertraline - Group B</title>
            <description>received Sertraline 50 mg/day for 7 days.After 7 days, received telenzepine for 21 days total at 1, 2, and 3 mg/day for 7 days each.</description>
          </group>
          <group group_id="O3">
            <title>Sertraline Plus Telenzepine - Group C</title>
            <description>received Sertraline 100 mg/day for 7 days.After 7 days, received telenzepine for 21 days total at 1, 2, and 3 mg/day for 7 days each.</description>
          </group>
          <group group_id="O4">
            <title>Sertraline Plus Telenzepine - Group D</title>
            <description>received Sertraline 150 mg/day for 7 days.After 7 days, received telenzepine for 21 days total at 1, 2, and 3 mg/day for 7 days each.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in the Meal Calories Consumed</title>
          <description>The changes in the meal calories consumed was measured upon telenzepine treatment at the dose of 1 mg, 2 mg and 3 mg (i.e. end of every 7 days). The baseline was defined as on day 7 of sertraline treatment with no telenzepine for the specified meal. Food consumption was measured as calories consumed for breakfast, lunch, and dinner for all treatment groups on day 7 of each dose combination.</description>
          <units>calorie</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 mg telenzepine (breakfast)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-63.70" spread="76.50"/>
                    <measurement group_id="O2" value="-42.32" spread="144.91"/>
                    <measurement group_id="O3" value="-88.93" spread="99.56"/>
                    <measurement group_id="O4" value="-53.91" spread="125.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 mg telenzepine (breakfast)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.32" spread="82.34"/>
                    <measurement group_id="O2" value="23.70" spread="133.16"/>
                    <measurement group_id="O3" value="-2.32" spread="78.06"/>
                    <measurement group_id="O4" value="-67.36" spread="147.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 mg telenzepine (breakfast)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.59" spread="119.04"/>
                    <measurement group_id="O2" value="80.21" spread="170.09"/>
                    <measurement group_id="O3" value="68.21" spread="107.49"/>
                    <measurement group_id="O4" value="-28.81" spread="144.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 mg telenzepine (lunch)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.98" spread="75.12"/>
                    <measurement group_id="O2" value="14.32" spread="66"/>
                    <measurement group_id="O3" value="59.69" spread="107.11"/>
                    <measurement group_id="O4" value="60.92" spread="91.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 mg telenzepine (lunch)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.91" spread="91.76"/>
                    <measurement group_id="O2" value="58.39" spread="129.87"/>
                    <measurement group_id="O3" value="144.50" spread="131.55"/>
                    <measurement group_id="O4" value="12.09" spread="111.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 mg telenzepine (lunch)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.36" spread="171.6"/>
                    <measurement group_id="O2" value="-119.01" spread="173.82"/>
                    <measurement group_id="O3" value="2.92" spread="110.29"/>
                    <measurement group_id="O4" value="-4.94" spread="153.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 mg telenzepine (supper)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.92" spread="110.88"/>
                    <measurement group_id="O2" value="47.66" spread="62.55"/>
                    <measurement group_id="O3" value="87.01" spread="171.07"/>
                    <measurement group_id="O4" value="-79.49" spread="126.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 mg telenzepine (supper)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.16" spread="129.51"/>
                    <measurement group_id="O2" value="-20.85" spread="139.59"/>
                    <measurement group_id="O3" value="-13.10" spread="182.34"/>
                    <measurement group_id="O4" value="-12.21" spread="152.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 mg telenzepine (supper)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.26" spread="140.61"/>
                    <measurement group_id="O2" value="61.88" spread="107.28"/>
                    <measurement group_id="O3" value="-22.98" spread="183.93"/>
                    <measurement group_id="O4" value="42.85" spread="107.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety of Sertraline and Telenzepine Combination</title>
        <description>safety of the drug combination was measured in terms of number of adverse events during the study period.</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Telenzepine - Group A</title>
            <description>received Sertraline 0 mg/day for 7 days.After 7 days, received telenzepine for 21 days total at 1, 2, and 3 mg/day for 7 days each.</description>
          </group>
          <group group_id="O2">
            <title>Telenzepine Plus Sertraline - Group B</title>
            <description>received Sertraline 50 mg/day for 7 days.After 7 days, received telenzepine for 21 days total at 1, 2, and 3 mg/day for 7 days each.</description>
          </group>
          <group group_id="O3">
            <title>Sertraline Plus Telenzepine - Group C</title>
            <description>received Sertraline 100 mg/day for 7 days.After 7 days, received telenzepine for 21 days total at 1, 2, and 3 mg/day for 7 days each.</description>
          </group>
          <group group_id="O4">
            <title>Sertraline Plus Telenzepine - Group D</title>
            <description>received Sertraline 150 mg/day for 7 days.After 7 days, received telenzepine for 21 days total at 1, 2, and 3 mg/day for 7 days each.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety of Sertraline and Telenzepine Combination</title>
          <description>safety of the drug combination was measured in terms of number of adverse events during the study period.</description>
          <units>number of adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Telenzepine - Group A</title>
          <description>received Sertraline 0 mg/day for 7 days.After 7 days, received telenzepine for 21 days total at 1, 2, and 3 mg/day for 7 days each.</description>
        </group>
        <group group_id="E2">
          <title>Telenzepine Plus Sertraline - Group B</title>
          <description>received Sertraline 50 mg/day for 7 days. After 7 days, received telenzepine for 21 days total at 1, 2, and 3 mg/day for 7 days each.</description>
        </group>
        <group group_id="E3">
          <title>Telenzepine Plus Sertraline - Group C</title>
          <description>received Sertraline 100 mg/day for 7 days. After 7 days, received telenzepine for 21 days total at 1, 2, and 3 mg/day for 7 days each.</description>
        </group>
        <group group_id="E4">
          <title>Telenzepine Plus Sertraline - Group D</title>
          <description>received Sertraline 150 mg/day for 7 days. After 7 days, received telenzepine for 21 days total at 1, 2, and 3 mg/day for 7 days each.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vomitting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated fasting glucose</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Head ache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased urinary frequency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Monica Tettamanti, MSc</name_or_title>
      <organization>Theracos, Inc</organization>
      <phone>617-643-5696</phone>
      <email>mtettamanti@ccib.mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

